Accipiter Biosciences Inc. filed a Form D with the Securities and Exchange Commission on 2026-07-28.
Accipiter Biosciences Inc. filed a Form D notice of an exempt securities offering with the SEC on July 28, 2026. The filing reports $10.49M sold. Its industry group is Biotechnology. It names Matthew Bick (Executive Officer, Director, Promoter), Hector De Jesus Rincon Arano (Executive Officer, Director, Promoter), Javier Castellanos (Executive Officer, Director, Promoter) (SEC Form D, July 28, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Accipiter Biosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-07-28 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Accipiter Biosciences Inc.
Free to see. No signup.
More on the people and the money behind Accipiter Biosciences Inc., from the filings we hold.
Biotechnology raises by companies based in Washington, filed within 90 days of this one, largest first.
Get an email when Accipiter Biosciences Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Accipiter Biosciences Inc. raises, hires or launches. No email unless you switch it on.
Watch Accipiter Biosciences Inc. →Get the full cited report on Accipiter Biosciences Inc.
What the filing shows about Accipiter Biosciences Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Accipiter Biosciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Accipiter Biosciences Inc.'s address as 1616 Eastlake Ave E., Suite 208, Seattle, WA 98102.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Accipiter Biosciences Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Accipiter Biosciences Inc. See pricing
Accipiter Biosciences Inc. is a registered filer with the SEC (CIK 1973963) and has filed since 2023-05-02. 3 filings are on record, the latest on 2026-07-28.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Accipiter Biosciences Inc.'s Form D of 2026-07-28 names Matthew Bick, Hector De Jesus Rincon Arano, Javier Castellanos and 4 more as its officers, directors or promoters.
Its new offerings report $19.06M sold across 3 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $10.49M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
Accipiter Biosciences designs de novo, multifunctional protein biologics to treat complex diseases through advanced computational protein design.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Matthew Bick is named as Executive Officer and Director and Promoter on the Form D that Accipiter Biosciences Inc. filed with the SEC on 28 July 2026, one of 7 people that filing names.
Hector De Jesus Rincon Arano is named as Executive Officer and Director and Promoter on the Form D that Accipiter Biosciences Inc. filed with the SEC on 28 July 2026, one of 7 people that filing names.
Javier Castellanos is named as Executive Officer and Director and Promoter on the Form D that Accipiter Biosciences Inc. filed with the SEC on 28 July 2026, one of 7 people that filing names.
Heather Redman is named as Director on the Form D that Accipiter Biosciences Inc. filed with the SEC on 28 July 2026, one of 7 people that filing names.
Randall Schatzman is named as Director on the Form D that Accipiter Biosciences Inc. filed with the SEC on 28 July 2026, one of 7 people that filing names.
William Canestaro is named as Executive Officer on the Form D that Accipiter Biosciences Inc. filed with the SEC on 28 July 2026, one of 7 people that filing names.
Jose Antonio Mesa Cejudo is named as Director on the Form D that Accipiter Biosciences Inc. filed with the SEC on 28 July 2026, one of 7 people that filing names.
7 people named on the filing — 4 holding an executive role and 3 as directors only.
Named as of the 2026-07-28 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Accipiter Biosciences Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Accipiter Biosciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Accipiter Biosciences Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Accipiter Biosciences Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Accipiter Biosciences Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (accipiterbio.com).
Each opens in a new tab, filled in for Accipiter Biosciences Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises, week of 2026-07-27 · Biotech raises in Seattle
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/accipiter-biosciences-inc-form-d-26000002